Cancer Cell Biology: How Normal Cells Become Cancerous

Oncogenes and Tumor Suppressors

Cancer-causing mutations affect two broad categories of genes. Proto-oncogenes are normal genes that encode proteins promoting cell growth and division, such as growth factor receptors, signal transduction kinases, and transcription factors. When a proto-oncogene is mutated in a way that makes its protein product constitutively active or overexpressed, it becomes an oncogene, continuously driving cell proliferation regardless of whether appropriate external signals are present. Common oncogenes include Ras (mutated in roughly 30 percent of all human cancers), HER2/Neu (amplified in about 20 percent of breast cancers), and Myc (overexpressed in many cancer types). Oncogene mutations are typically dominant, meaning a single mutant copy is sufficient to promote cancer.

Tumor suppressor genes encode proteins that restrain cell growth, promote DNA repair, or trigger apoptosis when the cell is damaged. The retinoblastoma protein (Rb) blocks cell cycle progression at the G1/S transition, and p53 responds to DNA damage by halting the cell cycle or activating apoptosis. When both copies of a tumor suppressor gene are inactivated by mutation or deletion, the cell loses an essential brake on proliferation. This two-hit requirement explains why inherited cancer syndromes, in which one defective copy is inherited, show a dramatically elevated cancer risk: only one additional mutation in the remaining copy is needed, rather than the two independent mutations required in normal individuals.

The Hallmarks of Cancer

In 2000, Douglas Hanahan and Robert Weinberg published an influential framework identifying six capabilities that a normal cell must acquire to become fully cancerous. These hallmarks, updated in 2011 with additional capabilities, provide a roadmap for understanding the complex biology of cancer. The original six hallmarks are self-sufficiency in growth signals (the cell produces its own growth factors or has constitutively active receptors), insensitivity to anti-growth signals (inactivation of Rb and similar pathways), evasion of apoptosis (overexpression of Bcl-2, loss of p53), limitless replicative potential (activation of telomerase to prevent telomere shortening), sustained angiogenesis (secretion of VEGF to recruit blood vessels), and tissue invasion and metastasis (loss of cell adhesion molecules, acquisition of motility).

The 2011 update added two enabling characteristics and two emerging hallmarks. Genomic instability and mutation provide the genetic variation from which cancer-promoting mutations are selected. Tumor-promoting inflammation, driven by immune cells inadvertently supplying growth factors and survival signals, creates a supportive microenvironment. The emerging hallmarks include reprogramming of cellular energy metabolism (the Warburg effect, in which cancer cells preferentially use glycolysis even in the presence of oxygen) and evasion of immune destruction (mechanisms that prevent T cells and natural killer cells from recognizing and eliminating cancer cells).

Multi-Step Carcinogenesis

Cancer does not arise from a single mutation. The transformation from a normal cell to a fully malignant cancer typically requires the accumulation of 4 to 7 driver mutations acquired over years or decades. This multi-step process explains why cancer incidence increases sharply with age: the longer a person lives, the more time there is for the necessary mutations to accumulate. Colorectal cancer provides a well-studied model of stepwise progression. Normal colonic epithelium first acquires an APC mutation, leading to increased proliferation and the formation of a small polyp. Subsequent mutations in KRAS (activating the Ras pathway), SMAD4 (disrupting TGF-beta signaling), and p53 (disabling the DNA damage checkpoint) progressively transform the benign polyp into an invasive adenocarcinoma.

In addition to the 4 to 7 driver mutations that directly confer growth advantages, cancer genomes typically contain dozens to thousands of passenger mutations that do not contribute to cancer development but were present in the cell at the time of clonal expansion. Large-scale genome sequencing projects have cataloged the mutational landscapes of many cancer types, revealing characteristic mutation patterns (mutational signatures) that reflect the mutagenic processes at work, such as ultraviolet radiation in melanoma, tobacco smoke carcinogens in lung cancer, and defective DNA mismatch repair in certain colorectal and endometrial cancers.

Genomic Instability

Normal cells maintain their genomes with remarkable fidelity through multiple overlapping repair systems, including mismatch repair, base excision repair, nucleotide excision repair, and homologous recombination. Cancer cells frequently acquire mutations that compromise these repair systems, accelerating the rate at which new mutations accumulate and providing the raw material for further cancer evolution. BRCA1 and BRCA2, for example, are essential components of the homologous recombination repair pathway. Inherited mutations in these genes cause a dramatically increased risk of breast and ovarian cancer because cells lacking functional BRCA proteins accumulate chromosomal aberrations at an accelerated rate.

Chromosomal instability (CIN), characterized by gains and losses of whole chromosomes or large chromosomal segments during cell division, is another common feature of cancer. Many cancers display aneuploidy, with chromosome numbers that deviate significantly from the normal 46. This chromosomal chaos can amplify oncogenes (by duplicating the chromosome segment carrying the oncogene) or delete tumor suppressors (by losing the chromosome segment carrying them), both of which accelerate cancer progression.

The Tumor Microenvironment

A tumor is not simply a mass of cancer cells. It is a complex ecosystem that includes cancer cells, blood vessels, immune cells, fibroblasts, and extracellular matrix. Cancer-associated fibroblasts (CAFs) remodel the extracellular matrix and secrete growth factors that support tumor growth. Tumor-associated macrophages (TAMs) are often co-opted by the tumor to suppress anti-tumor immune responses and promote angiogenesis. The extracellular matrix itself undergoes significant changes in composition and stiffness that can promote invasion and metastasis.

Angiogenesis, the formation of new blood vessels, is essential for tumor growth beyond a diameter of roughly 1 to 2 millimeters, the limit of oxygen diffusion. Tumors stimulate angiogenesis by secreting vascular endothelial growth factor (VEGF) and other pro-angiogenic signals. However, tumor blood vessels are typically abnormal: they are leaky, poorly organized, and create regions of low oxygen (hypoxia) within the tumor. Hypoxia activates the transcription factor HIF-1, which promotes further VEGF expression, metabolic adaptation to low oxygen, and increased invasiveness. Anti-angiogenic therapies such as bevacizumab (Avastin) target VEGF to starve tumors of their blood supply, though resistance to these therapies eventually develops in most cases.

Metastasis

Metastasis, the spread of cancer cells from the primary tumor to distant organs, is responsible for approximately 90 percent of cancer deaths. The metastatic process is remarkably inefficient: millions of cancer cells may enter the bloodstream daily from a primary tumor, but only a tiny fraction (estimated at less than 0.01 percent) survive to form metastatic colonies. To metastasize successfully, a cancer cell must detach from the primary tumor, invade through the basement membrane and surrounding tissue, enter a blood or lymphatic vessel (intravasation), survive in the circulation, exit the vessel at a distant site (extravasation), and establish a growing colony in the new tissue.

The epithelial-mesenchymal transition (EMT) is a developmental program that cancer cells reactivate to acquire invasive properties. During EMT, epithelial cancer cells lose their cell-cell adhesion (partly through downregulation of E-cadherin), gain motility, and develop resistance to apoptosis. Transcription factors including Snail, Slug, Twist, and ZEB1 drive this transition. At the distant metastatic site, the reverse process, mesenchymal-epithelial transition (MET), may occur as cancer cells re-establish epithelial characteristics to proliferate and form a secondary tumor. Certain cancers show strong organ preferences for metastasis: breast cancer frequently metastasizes to bone, lung, liver, and brain, while prostate cancer preferentially spreads to bone. These patterns reflect compatibility between the cancer cells and the microenvironment of the target organ.

Cancer Immunology and Immunotherapy

The immune system can recognize and destroy cancer cells, but tumors evolve mechanisms to evade immune surveillance. Cancer cells may downregulate the surface molecules (MHC class I) that present tumor antigens to cytotoxic T cells, making themselves invisible. They may express immune checkpoint proteins such as PD-L1 that bind to PD-1 on T cells and deliver an inhibitory signal, effectively turning off the anti-tumor immune response. They may recruit regulatory T cells and myeloid-derived suppressor cells that actively suppress immune responses within the tumor microenvironment.

Immune checkpoint inhibitors, antibodies that block PD-1, PD-L1, or CTLA-4, have revolutionized cancer treatment by releasing the brakes on anti-tumor T cell responses. These therapies have produced durable responses in subsets of patients with melanoma, lung cancer, kidney cancer, and many other tumor types. CAR-T cell therapy, in which a patient own T cells are engineered to express a chimeric antigen receptor targeting a tumor-specific surface protein, has shown remarkable efficacy against certain blood cancers, particularly B cell acute lymphoblastic leukemia and diffuse large B cell lymphoma.